Literature DB >> 9872846

Role of nitric oxide in sepsis-associated pulmonary edema.

F Hinder1, H D Stubbe, H Van Aken, R Waurick, M Booke, J Meyer.   

Abstract

Transient pulmonary hypertension after inhibition of nitric oxide synthase (NOS) does not alter pulmonary reflection coefficients or lymph flows in endotoxemic sheep. To test the effects of persistent pulmonary hypertension induced by N omega-nitro-L-arginine methylester (L-NAME) and of inhaled NO on pulmonary edema, 18 sheep (three groups) were chronically instrumented with pulmonary artery catheters, femoral arterial fiberoptic thermistor catheters, and tracheostomy. The awake, spontaneously breathing animals received Salmonella typhi endotoxin (lipopolysaccharide; LPS) (10 ng/kg/ min) for 28 h. After 24 h, an airflow of 6 L/min was delivered through the tracheostomy. One group of animals (L-NAME/air) received L-NAME intravenously (25 mg/kg + 5 mg/kg/h) and breathed air. The second group (L-NAME/NO) was given L-NAME and NO (40 ppm) was added to the airflow. The third group was given NaCl 0.9% and breathed air (NaCl/air). Extravascular lung water was measured through the double-indicator dilution technique. Endotoxemia caused pulmonary edema, which was aggravated by L-NAME. Breathing of NO normalized pulmonary artery pressure (Ppa) and ameliorated pulmonary edema. Inhalation of NO may therefore be a therapeutic option for pulmonary edema associated with pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9872846     DOI: 10.1164/ajrccm.159.1.9806024

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  LYRM03, an ubenimex derivative, attenuates LPS-induced acute lung injury in mice by suppressing the TLR4 signaling pathway.

Authors:  Hui-Qiong He; Ya-Xian Wu; Yun-Juan Nie; Jun Wang; Mei Ge; Feng Qian
Journal:  Acta Pharmacol Sin       Date:  2017-01-23       Impact factor: 6.150

2.  Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome.

Authors:  Tsin W Yeo; Daniel A Lampah; Emiliana Tjitra; Retno Gitawati; Christabelle J Darcy; Catherine Jones; Enny Kenangalem; Yvette R McNeil; Donald L Granger; Bert K Lopansri; J Brice Weinberg; Ric N Price; Stephen B Duffull; David S Celermajer; Nicholas M Anstey
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

3.  Inhaled nitric oxide reduces lung edema during fluid resuscitation in ovine acute lung injury.

Authors:  Henning D Stubbe; Martin Westphal; Hugo Van Aken; Christoph Hucklenbruch; Stefan Lauer; Uli R Jahn; Frank Hinder
Journal:  Intensive Care Med       Date:  2003-05-24       Impact factor: 17.440

Review 4.  Nitric Oxide Bioavailability in Obstructive Sleep Apnea: Interplay of Asymmetric Dimethylarginine and Free Radicals.

Authors:  Mohammad Badran; Saeid Golbidi; Najib Ayas; Ismail Laher
Journal:  Sleep Disord       Date:  2015-05-06

5.  R-100 improves pulmonary function and systemic fluid balance in sheep with combined smoke-inhalation injury and Pseudomonas aeruginosa sepsis.

Authors:  Hiroshi Ito; Erik Malgerud; Sven Asmussen; Ernesto Lopez; Andrew L Salzman; Perenlei Enkhbaatar
Journal:  J Transl Med       Date:  2017-12-28       Impact factor: 5.531

6.  Cell-specific nitric oxide synthase-isoenzyme expression and regulation in response to endotoxin in intact rat lungs.

Authors:  Monika Ermert; Clemens Ruppert; Andreas Günther; Hans-Rainer Duncker; Werner Seeger; Leander Ermert
Journal:  Lab Invest       Date:  2002-04       Impact factor: 5.662

7.  Sodium Hydrosulphide alleviates remote lung injury following limb traumatic injury in rats.

Authors:  Jiaolin Ning; Liwen Mo; Hongzhi Zhao; Kaizhi Lu; Xinan Lai; Xianghong Luo; Hailin Zhao; Daqing Ma
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

8.  New perspectives of nitric oxide donors in cardiac arrest and cardiopulmonary resuscitation treatment.

Authors:  Peter Kruzliak; Olga Pechanova; Tomas Kara
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.